Candel Therapeutics Adds Regulatory Expert to Board Ahead of Key BLA Submission
Event summary
- Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors on September 8, 2026.
- Zimmermann brings over 30 years of global regulatory affairs and quality expertise, currently serving as Executive Vice President at Inventiva S.A.
- The move comes as Candel prepares for its planned Biologics License Application (BLA) submission for aglatimagene besadenovec in Q4 2026.
- Aglatimagene is Candel's lead multimodal immunotherapy candidate for treating solid tumors, with over 1,000 patients dosed in clinical trials.
The big picture
Candel Therapeutics is strengthening its governance ahead of a critical regulatory milestone, reflecting the biotech industry's focus on regulatory expertise for successful product approvals. The appointment underscores the strategic importance of regulatory affairs in navigating the complex path to commercialization for innovative cancer therapies. With over 1,000 patients dosed and multiple regulatory designations secured, Candel is positioning itself for a potential transformative impact in the oncology space.
What we're watching
- Regulatory Strategy
- How Zimmermann's expertise will shape Candel's BLA submission and potential commercial launch.
- Commercial Readiness
- Whether Candel can successfully transition from clinical-stage to commercial-stage company.
- Therapeutic Potential
- The pace at which aglatimagene besadenovec can demonstrate broad anti-tumor activity across solid tumors.
Related topics